Receptors for the neuropeptide somatostatin (SS) were evaluated in vitro and in vivo in various human lymphatic tissues, ie, thymus, spleen, and lymph nodes; thymic carcinoids and thymomas were also tested. The receptors were measured in vitro using receptor autoradiography on tissue sections incubated with the SS analog '251-[Ty?]-o~treo-tide or '251-[Le~8,D-TrpZZ,Ty85]-SS-28. All tissues were SS-receptor positive for either radioligand, except the thymomas. In thymic tissue, the receptors were diffusely located in the medulla, presumably on epithelial cells. In the spleen, the red pulp was strongly labeled. In the lymph nodes, the germinal centers were preferentially labeled. In all tissues, the receptors were of high affinity (kd thymus, EVERAL REGULATORY peptides found in the brain S and the gastrointestinal tract have also been localized in the lymphatic tissues, and were shown to act on cells of the immune system. This has been reported for the vasoactive intestinal peptide (VIP), substance P (SP), and somatostatin (SS), which may act separately or interact with each other.'" SS has been shown to inhibit murine lymphocyte proliferation,'6 Ig synthesis: and the release of colony-stimulating factor (CSF) from activated lymphocytes.' Moreover, SS enhances the formation of leukocyte-migration inhibiting factor in activated lymphocyte^.^ High-affinity SS receptors mediating SS effects were described in murine and human lymphatic tissue.'-'' We have recently identified high-affinity SS receptors in the human gut-associated lymphatic tissue (GALT), preferentially located within germinal centers." Furthermore, some human lymphomas have increased uptake of radiolabeled SS analogs, a finding that suggests that lymphomas express SS receptors.'* In the present study, we have evaluated the presence of SS receptors in other human lymphatic tissues, including thymus of newborns and adults, spleen and lymph nodes of adults, as well as in a thymoma and in thymic carcinoids. SS receptors were investigated in vitro using SS receptor autoradiography and in vivo in the patient with SS analog scintigraphy.I3-"
S and the gastrointestinal tract have also been localized in the lymphatic tissues, and were shown to act on cells of the immune system. This has been reported for the vasoactive intestinal peptide (VIP), substance P (SP), and somatostatin (SS), which may act separately or interact with each other. ' " SS has been shown to inhibit murine lymphocyte proliferation, '6 Ig synthesis: and the release of colony-stimulating factor (CSF) from activated lymphocytes.' Moreover, SS enhances the formation of leukocyte-migration inhibiting factor in activated lymphocyte^.^ High-affinity SS receptors mediating SS effects were described in murine and human lymphatic tissue.'-'' We have recently identified high-affinity SS receptors in the human gut-associated lymphatic tissue (GALT), preferentially located within germinal centers." Furthermore, some human lymphomas have increased uptake of radiolabeled SS analogs, a finding that suggests that lymphomas express SS receptors.'* In the present study, we have evaluated the presence of SS receptors in other human lymphatic tissues, including thymus of newborns and adults, spleen and lymph nodes of adults, as well as in a thymoma and in thymic carcinoids. SS receptors were investigated in vitro using SS receptor autoradiography and in vivo in the patient with SS analog scintigraphy.I3-" Table 1 ) and of lymph nodes (Table 2) were collected at the University Hospital in Beme and Kantonsspital Lucerne (Switzerland). In addition, five spleens were obtained from the Erasmus University Hospital in Rotterdam. All samples were obtained during surgical intervention performed for diagnostic or therapeutic reasons, with informed consent of all patients or their parents, and in accord with the Helsinki Doctrine on Human Experimentation. With the exception of the six thymic neoplasms, the tissue samples were histopathologically normal, or displayed mild, reactive changes. All tissue samples were taken fresh at operation and stored frozen at -70°C.
MATERIALS AND METHODS

Samples. All samples of thymic tissues (listed in
SS receptor autoradiography. Ten-micron and 2 0 -~m thick cryostat sections of the tissue samples were processed for SS receptor autoradiography as described in detail previously. 16 The radioligands used were the SS analogs 1251- recept~rs.l'~~* Both ligands were iodinated, purified on high pressure liquid chromatography (HPLC) column (specific activity, 2,000 Ci/mmol) and characterized in standard binding assays as described previ~usly.'~~'~ For autoradiography, tissue sections were mounted on precleaned microscope slides and stored at -20°C for at least 3 days to improve adhesion of tissue to the slide. Sections were then incubated for 2 hours at ambient temperature in the presence of the iodinated ligand (0.15 to 0.30 X lo6 disintegrations per minute [dpm]/mL, approximately 80 to 160 pmol/L). The incubation solution was 170 mmol/L Tris-HCI buffer (pH 7.4) containing 1% bovine serum albumin (BSA), bacitracin (40 pg/mL), and MgCl, ( 5 mmol/L) to inhibit endogenous proteases. Nonspecific binding was determined by adding 1 pmol/L solution of unlabeled [Ty?]-octreotide or SS-28. Incubated sections were washed twice for 5 minutes in cold incubation buffer containing 0.25% BSA and then in buffer alone, and were dried quickly. Compared with previous procedures of washing in distilled water,16 the present method of washing in buffer resulted in much better histologic preservation of the lymphatic tissues." Finally, the sections were apposed to 3H-Ultrofilms (Cambridge Research Inc, Nussdorf, Germany) and exposed for I week in x-ray cassettes.
In selected cases, displacement experiments were performed in successive tissue sections using increasing concentrations of various biologically active or inactive peptides.I6 In addition, saturation experiments using increasing concentrations of '251-[Ty?]-octreotide were performed on tissue sections.16 Moreover, the effect of nucleotides was tested on the '2SI-[Tyr3]-octreotide binding using increasing concentrations (io-' to io-' mol/L) of guanosine triphosphate (GTP). The autoradiograms were quantified using a computer-assisted image-processing system previously described. SS receptor scintigraphy was performed as described in detail p r e~i o u s l y . '~~'~ A dose of 7 to 10 pg of "'In-[DTPAI-octreotide corresponding to I85 to 259 MBq ofradioactivity was administered as a single intravenous (IV) injection. Planar images were obtained with a large field of view y camera (Counterbalance 3700 and ROTA 11; Siemens, Hoffman Estates, IL). A standard protocol was used to scan the thorax and abdomen region in In vivo scintigraphy. all patients. All cases had at least one antero-posterior and one postero-anterior scan of the thorax, including the neck region, and of the abdomen 24 hours after tracer injection. The acquisition parameters for planar images were 300,000 and 500,000 preset counts for the necklchest and abdomen images, respectively.
RESULTS
Thymus, spleen, and lymph nodes express SS binding sites. In all three tissues these binding sites can be characterized as being of high affinity, specific for biologically active SS analogs, and GTP dependent (Tables I , 2 , and 3).
Normal thymus. All samples of normal thymus contained SS binding sites ( Table 1 ). In young children as well as in adult individuals, the SS binding sites were located in the medulla (Fig 1) . Because the medulla appears diffusely and homogeneously labeled and because the present autoradiographic technique does not allow us to assign the label to a given cell, SS binding sites may be located either on vascular epithelial cells, stroma, reticulo-endothelial cells, or on lymphocytes. No significant labeling was observed in the cortex nor in Hassal's corpuscles. Saturation experiments with increasing concentrations of '251-[Tyr3]-octreotide showed that the SS binding in the thymic medulla from a newborn child is saturable and of high affinity. Scatchard plots of the data showed a dissociation constant (kd of 0.84 nmol/L and total number of sites (Bmax) equivalent to 83 fmol/mg protein (Fig 2) . This binding was specific because SS and bioactive SS analogs, ie, octreotide, were able to displace the radioligand in the high-affinity range, whereas the biologically inactive analog SS-28 (1-12) did not dis- place the radioligand (Fig 3) . Furthermore, SS binding was GTP-dependent ( Table 3 ). The binding characteristics obtained in child thymus were also obtained in adult thymus. The present results are similar to the SS binding characteristics found in other SS target tissues. In addition, one thymus from a patient with myasthenia gravis was positive for SS binding sites, again with the label preferentially located in the medullary area.
Thymicneoplasms. Table 1 shows the results ofthe evaluation of SS binding sites in six human thymic neoplasms. Whereas the four thymomas were negative, the two thymic carcinoids were positive.
In vivo scintigraphy with ''LIn-[DTPA]-octreotide performed in more than 800 patients suffering from various types of mostly neuroendocrine tumors never did identify hot spots in the thymus region. However, one patient with a thymic carcinoid was scanned in vivo and showed accumulation of the radioligand in the primary tumor and its mediastinal metastases.
In all five spleens tested, SS binding sites were preferentially located in the red pulp, as seen in the autoradiography picture of Fig 4. Binding was specific and of high affinity because [Tyr'l-octreotide and SS-28 were able to displace the radioligand in the high affinity range. Conversely, unrelated peptides such as luteinizing hormone-releasing hormone (LHRH) were inactive (Fig 3) . In a binding experiment using successive cryostat sections from one of the spleens, the dissociation constant (kd) was calculated from Scatchard plots to be 1.6 nmol/L. The estimated B, , , value was 145 fmol/mg protein. Other receptor autoradiographic experiments on spleen tissue sections showed that '251-[Tyr3]-octreotide binding was GTP-dependent (Table  3) .
In vivo scintigraphy using '''In-[DTPA]-o~treotide identified a strongly labeled spleen in 800 patients tested routinely for tumor diagnosis. An example is shown in Fig 5. This labeling represents specific SS binding sites, as implied by our in vitro results and by the fact that the spleen labeling in vivo is strongly reduced in patients pretreated with octreotide (Fig 5) .
In all 15 lymph nodes tested in vitro, high-affinity SS binding sites were identified within large Spleen.
Lymph nodes.
germinal centers (Table 2 and Fig 6) . In addition, in some cases, a diffuse, weak labeling was seen in the whole lymph node as well (Fig 6) . Binding was specific and of high affinity because both SS and bioactive SS analogs such as octreotide were able to displace the radioligand in the nanomolar range, whereas the biologically inactive SS-28 (1-12) was not (Fig 3) . In a case of lymphatic hyperplasia, the k, calculated from Scatchard plot was 0.62 nmol/L and the estimated B,,, was 128 fmol/mg protein. Binding was GTP-dependent (Table 3) . Similar binding charactenstics of lymph nodes were found in lymphatic hyperplasia and in granulomatous lymphadenitis caused by cat scratch disease.
The lymph nodes, thymi, and spleens labeled in vitro with 'z51-[Tyr3]-octreotide could also be labeled with the 
DISCUSSION
The present study describes for the first time the presence of SS binding sites in human lymphatic tissues such as newborn and adult thymus, spleen, and lymph nodes. This observation relates to a previous study describing SS receptors in the human GALT." As in the GALT, the SS binding sites in the presently investigated tissues may be specific SS receptors because a GTP-dependency could be observed. Moreover, they appear to belong to the SS1 receptor subtype, because the SS octapeptide octreotide as well as SS-14 or SS-28 show high-affinity binding to the r e~e p t o r . "~'~~'~,~~ Recently, the genes encoding three human SS-receptor subtypes have been cloned and sequenced21r22; one of these, the SSTR2 type, shows high affinity not only for SS-14 but also for small synthetic SS analogs such as MK 678 or octreotideZ3; recent data suggest that it is identical to the pharmacologically characterized SS 1 receptor s~btype.'~ Therefore, lymphatic tissues investigated in the present report probably express the SSTR2 subtype; however, we cannot completely exclude the possibility that a further subtype, different from SSTRl and SSTR3, is also expressed.
Tli.vmus. The human thymic medulla of both newborn and adult contains high-affinity SS receptors. It is presently not possible to assign these receptors to a defined cell type in the medulla. The very weak staining of the cortex suggests that the cells located predominantly in this area, ie, lymphatic cells, have no SS receptors. Thus, in the medulla, strong candidates for the expression of SS receptors could be the epithelial cells, densely packed in this region. Some of these epithelial cells can be labeled with A2B5, a monoclonal antibody (MoAb) directed against a complex neuronal ganglioside found on the cell surface of neurons and neuroendocrine ~e l l s .~~, '~ Interestingly, some of the medullary epithelial cells, including AfB5-positive cells, were shown to contain various thymic hormones," strongly suggesting that these cells have neuroendocrine characteristics. Because most normal neuroendocrine tissues, as well as the thymic carcinoids (which originate from neuroendocrine cells), are known to express SS it is conceivable that these medullary "neuro-endocrine-like" epithelial cells also bear SS receptors. However, because of the diffuse and homogeneous labeling pattern, it is possible that the other nonneuroendocrine types of epithelial cells were also labeled, and it cannot be completely excluded that some mature medullary thymocytes or isolated B lymphocytes in the medulla do contain SS receptors.
In addition to being the primary lymphatic organ generating effectors of cell-mediated immunity, the thymus can be considered a major endocrine gland responsible for the secretion by its epithelial cells of a heterogeneous family of polypeptide hormones such as thymulin, thymosins, and thym~poietin.'~ These peptides not only exert important For regulatory effects within the immune system, such as induction of proliferation and differentiation of T lymphocyte^:^ but also regulate the neuroendocrine system and are themselves subject to control by various hormones (prolactin, growth hormone, thyroid hormones, adrenocorticotropin
[ACTH], or opioids) through specific receptors located in the thymus.Z6'* Thus, these peptides represent an important interface between the immune and neuroendocrine system^.^^*^^
The functional role of SS and SS receptors should probably be considered under the same point of view, despite the lack of expt.lmenta1 data. In epithelial cells, SS may regulate the secretion of thymic hormones, in a way similar to its well-known inhibition of hormone release in virtually all neuroendocrine cells in the body. Moreover, and in analogy to the described action of SS in other lymphatic tissue, we may speculate that an SS effect relates to lymphopoiesis, perhaps by regulating the proliferation and specific functions of lymphocytes.'" Endogeneous SS should be available locally for that purpose because it was recently shown that the thymic medulla of the rat contains both SS mRNA and immunohistochemically detectable SS.30*3' Thymic neoplasms. Many well-differentiated neoplasms arising from SS receptor-positive tissues contain SS receptors." This principle does not seem to be valid for the four thymomas studied in this report. However, the two thymic carcinoids were SS receptor positive. This is not surprising, because these neoplasms are thought to arise from neuroendocrine cells located in the thymus, and is in keep ing with our previous observation that most of the carcinoids, independently of their location, usually express SS receptors.16 Thymic carcinoids, as their gastrointestinal or bronchial counterparts, may therefore be detected by in vivo scanning technique~''-'~ using radiolabeled SS analogs: the one patient with a thymic carcinoid scanned in vivo showed accumulation of the radioligand in the primary tumor and its mediastinal metastases. Furthermore, it may be worthwhile to evaluate whether these tumors can be treated by SS analogs such as octreotide.
Spleen. and in vivo in many human t~m o r s . '~* '~~~~*~~ In most of these cases, we could establish that even tumors with a relatively low density of SS receptors or with a nonhomogeneous tissue distribution of SS receptors in vitro could be identified and localized by means of in vivo SS scintigraphy. Therefore, it is intriguing that SS receptor-positive lymph nodes as well as normal thymus have not been detected by in vivo scintigraphy. It is possible, but improbable, that the sensitivity of the in vivo method is not sufficient for the detection of these receptors, especially in regions with a higher background such as the abdomen or the skull base. However, a more attractive possibility is that such in vitro/ in vivo discrepancies have a biologic origin. Hypothetically, the SS receptor turnover in lymphatic tissues could be much slower than in neoplasms and pituitary glands. This would mean that much less receptor-radioligand complex is being internalized in lymphatic tissue compared with internalization in neoplastic tissue and pituitary gland: this would result in a less intensive labeling of the tissue in vivo, which seems to depend not only on the receptor density but also on the capacity of internalization of the radi01igand.l~ symptomatic therapy of certain cancers in humans, very few reports on immunologic side effects have appeared. However, preliminary data from one group of investigators support the existence of immunologic reactions to SS36; clearly, the present results could stimulate more clinical studies in this direction.
Another conclusion of the present report relates to radiotherapy. The finding of a high number of SS receptors in various tumors recently generated the idea of targeting 8-emitting isotope-linked SS ligands to "bum out" selectively such However, according to our present in vitro data, normal tissues bearing SS receptors, particularly "central" and "peripheral" lymphatic tissues, are likely to be affected by such an approach. Potential functional consequences should be carefully investigated.
